mpox vaccine – Artifex.News https://artifex.news Stay Connected. Stay Informed. Fri, 13 Sep 2024 11:11:40 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://artifex.news/wp-content/uploads/2026/05/cropped-cropped-app-logo-32x32.png mpox vaccine – Artifex.News https://artifex.news 32 32 Mpox Vaccine: WHO grants first approval to ramp up response to disease in Africa and beyond https://artifex.news/article68638171-ece/ Fri, 13 Sep 2024 11:11:40 +0000 https://artifex.news/article68638171-ece/ Read More “Mpox Vaccine: WHO grants first approval to ramp up response to disease in Africa and beyond” »

]]>

The U.N. health agency chief called for “urgent” scale-up of procurement, donations and rollout to get the vaccine where it is needed most, along with other response measures. File
| Photo Credit: AP

The World Health Organization (WHO) said on Friday (September 13, 2024) it has granted its first authorisation for use of a vaccine against mpox in adults, calling it an important step toward fighting the disease in Africa and beyond.

The pre-qualification of the vaccine by Bavarian Nordic A/S means that donors such as GAVI the Vaccine Alliance and UNICEF can buy it. But supplies are limited because there’s only a single manufacturer.

“This first pre-qualification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” said WHO Director-General Tedros Adhanom Ghebreyesus.

The U.N. health agency chief called for “urgent” scale-up of procurement, donations and rollout to get the vaccine where it is needed most, along with other response measures.

Under the WHO authorisation, the vaccine can be administered in people aged 18 or above in a two-dose regimen. The approval says that while the vaccine is not currently licensed for those under 18 years old, it may be used in infants, children and adolescents “in outbreak settings where the benefits of vaccination outweigh the potential risks.”

Officials at the Africa Center for Disease Control (CDC) and Prevention said last month that nearly 70% of cases in Congo — the country hardest hit by mpox — are in children younger than 15, who also accounted for 85% of deaths.

On Thursday (September 12, 2024), the Africa CDC said 107 new deaths and 3,160 new cases had been recorded in the past week, just a week after it and WHO launched a continental response plan.

Mpox belongs to the same family of viruses as smallpox but causes milder symptoms such as fever, chills and body aches. People with more serious cases can develop lesions on the face, hands, chest and genitals.



Source link

]]>
Mpox patients lack medicine, food, in east DR Congo hospital https://artifex.news/article68600729-ece/ Tue, 03 Sep 2024 11:14:12 +0000 https://artifex.news/article68600729-ece/ Read More “Mpox patients lack medicine, food, in east DR Congo hospital” »

]]>

The hands of a patient with skin rashes caused by the mpox virus are pictured at the treatment center of Vijana Hospital in Kinshasa, Democratic Republic of Congo on August 30, 2024
| Photo Credit: Reuters

Dozens of feverish patients lay on thin mattresses on the floor of a makeshift mpox isolation ward in east Democratic Republic of Congo, as overstretched hospital workers grappled with drug shortages and lack of space to accommodate the influx.

Congo is the epicentre of an mpox outbreak that the World Health Organization declared to be a global public health emergency last month.

Vaccines are set to arrive within days to fight the new strain of the virus, while Congo’s President Felix Tshisekedi has allowed a first USD 10 million disbursement to fight the outbreak.

But at the hospital complex in the town of Kavumu, where 900 symptomatic patients have been taken in over the past three months, health workers are desperate for support.

“We run out of medicine every day,” said head doctor Musole Mulamba Muva. “There are many challenges we struggle to overcome with our local means,” he said, noting that donations from international organisations rapidly dwindled.

Last week there were 135 patients in the mpox ward, children and adults combined, crammed between three large plastic tents pitched into damp earth without a floor cover.

Relatives that usually provide the bulk of meals in underfunded public facilities such as the Kavumu hospital were banned from visiting the mpox ward to avoid contamination. “We do not have anything to eat,” said Nzigire Lukangira, the 32-year-old mother of a hospitalised toddler.

“When we ask for something to lower our children’s temperature, they do not give us anything,” she said, coaxing honey into her daughter’s mouth.

The head of Congo’s mpox response team, Cris Kacita, acknowledged that parts of the vast central African country lacked medicine and that dispatching donations, including 115 tonnes of medicine from the World Bank, was a priority.

Traditional remedies

Mpox causes flu-like symptoms and pus-filled lesions and, while usually mild, it can kill. Children, pregnant women and people with weakened immune systems are all at higher risk of complications.

Like other mothers in the Kavumu mpox ward, Lukangira had started improvising with traditional remedies to ease her baby’s pain. They dipped their fingers in potassium bicarbonate or salty lemon juice and popped their children’s blisters. Adult patients did the same to themselves.

Most cases came from the town itself and surrounding villages. Two other makeshift mpox wards have been set up in the area.

Local health ministry representative, doctor Serge Munyau Cikuru, called on the government to continue pushing for vaccines.

Kacita said high-risk contacts and nine priority areas had already been identified for the first vaccination stage.

There were 19,710 suspected cases of mpox reported since the start of the year in Congo by August 31, according to the health ministry. Of those, 5,041 were confirmed and 655 were fatal.



Source link

]]>
Monkeypox Cases Rising: How Worried Should You Be https://artifex.news/monkeypox-cases-rising-how-worried-should-you-be-10-points-6352133/ Fri, 16 Aug 2024 14:17:38 +0000 https://artifex.news/monkeypox-cases-rising-how-worried-should-you-be-10-points-6352133/ Read More “Monkeypox Cases Rising: How Worried Should You Be” »

]]>

Mpox has been a public health problem in parts of Africa for decades

New Delhi:
The World Health Organization has declared that an outbreak of mpox, a viral infection that spreads through close contact, represents a global health emergency for the second time in two years. Mpox causes flu-like symptoms and pus-filled lesions.

Here’s your 10-point cheat sheet to this big story

  1. While usually mild, mpox can kill. Children, pregnant women and people with weakened immune systems, such as those with HIV, are all at higher risk of complications. The WHO declared the recent outbreak of the disease a public health emergency after a new offshoot of the mpox virus, first identified in Democratic Republic of Congo, began spreading to other neighbouring countries.

  2. Two years ago, the WHO declared mpox was an emergency when a form of the disease, ‘clade IIb’, began to spread globally, largely among men who have sex with men. That outbreak was brought under control after behaviour change and safe sex practices, plus vaccines, helped people at risk protect themselves in many countries.

  3. But mpox has been a public health problem in parts of Africa for decades. The first ever human case was in Congo in 1970, and it has had outbreaks ever since. The current outbreak, Congo’s worst ever, has seen 27,000 cases and more than 1,100 deaths since January 2023, largely among children.

  4. Two strains of mpox are now spreading in Congo – the endemic form of the virus, ‘clade I’, and a new offshoot called ‘clade Ib’, with the term ‘clade’ referring to a form of the virus. The new offshoot has now moved from eastern Congo to Rwanda, Uganda, Burundi and Kenya.

  5. Sweden reported the first case of the new form, ‘clade Ib’, outside Africa on Thursday. A WHO spokesperson said the case reiterated the need for partnership, and the agency continues to advise against travel restrictions to stop the spread of mpox. Pakistan on Friday also confirmed a case of the mpox virus in a patient who had returned from a Gulf country, though it was unclear whether it was of the new variant or of the clade that has been spreading globally since 2022.

  6. But in 2022, a WHO appeal for $34 million to fight mpox got no take-up from donors, and there was huge inequity in who had access to vaccine doses. African countries had no access to the two shots used in the global outbreak, made by Bavarian Nordic and KM Biologics.

  7. Two years later that remains the case, although there are efforts to change that, the WHO said on Wednesday as it appealed for dose donations from countries with stockpiles. Africa CDC said it has a plan to secure doses, without elaborating further, but stocks are currently limited.

  8. Fatality rates vary, and depend heavily on the healthcare available to the sickest patients. In Congo in this outbreak, the rate across both ‘clade I’ and ‘clade Ib’ has been around 4 per cent. ‘Clade II’, which spread globally, was much less deadly.

  9. However, mpox is not COVID-19. There are tools that are proven to work to stop the spread and help those at risk, and it does not spread as easily. The challenge now, which the emergency declarations aim to highlight, is making sure those tools reach those who need them most, in Congo and neighbouring countries.

With inputs from Reuters

Waiting for response to load…



Source link

]]>
Africa mpox resurgence, with deadlier and more transmissable strain, fuels alarm https://artifex.news/article68496646-ece/ Wed, 07 Aug 2024 11:41:26 +0000 https://artifex.news/article68496646-ece/ Read More “Africa mpox resurgence, with deadlier and more transmissable strain, fuels alarm” »

]]>

Two years after a global outbreak, fears are rife that a new strain of mpox — previously known as monkeypox — identified in DR Congo and now also in several neighbouring countries could further spread.

Deadlier and more transmissible than previous forms, the mpox strain surging in the Democratic Republic of Congo (DRC) since September, known as the Clade Ib subclade, is spread person-to-person.

The World Health Organization (WHO) said on Sunday it was considering convening an expert committee to advise on whether to declare an international emergency, as it did during the global mpox outbreak in 2022.

The Clade Ib strain causes skin rashes across the whole body, unlike other strains where lesions and rashes are usually limited to the mouth, face and genitals.

The African Union health agency, Africa CDC, registered 14,479 confirmed and suspected cases of the strain and 455 deaths in DRC as of August 3, representing a mortality rate of around three percent.

But researchers in the vast Central African nation say the mortality rate from the strain can be as much as 10 percent among children.

The Congolese government acknowledged last month an “exponential increase” in cases.

“The disease has been seen in the displacement camps around Goma in North Kivu where the extreme population density makes the situation very critical,” Louis Albert Massing, medical coordinator for Doctors Without Borders in DRC said.

“The risks of explosion are real given the enormous population movements” in the conflict-ridden region, which borders several countries, he added.

Already, the Clade Ib strain has jumped national borders — in the last two weeks, cases have been reported in Uganda, Burundi, Rwanda and Kenya, Rosamund Lewis, the WHO’s technical lead for mpox, told AFP.

‘Raging’

Authorities in the four countries have confirmed mpox cases — Burundi in particular has reported 127 cases — without specifying the strain.

The eight-member East African Community (EAC) has urged governments to educate their citizens on how to protect themselves and prevent the spread of the disease.

Lewis, from the WHO, said it was the first time that the four countries lying to the east of DRC had reported mpox cases.

“Rwanda, Burundi, Uganda are countries that don’t have this disease in an endemic way… that means it’s an extension of the outbreak which is raging in the DRC and in Central Africa generally,” she said.

Africa CDC has also reported 35 suspected and confirmed cases, including two deaths, in Cameroon, 146 cases, including one death, in Congo Brazzaville, 227 cases in the Central African Republic, 24 in Nigeria, five in Liberia and four cases in Ghana.

In West Africa, Ivory Coast recently reported six confirmed non-fatal cases, five of which were in the economic capital Abidjan, without specifying the strain.

Detection capacity

Mpox was first discovered in humans in 1970 in the DRC, then called Zaire. It has since been mainly limited to certain West and Central African nations. Humans mainly catch it from infected animals, such as when eating bushmeat.

In May 2022, mpox infections surged worldwide, mostly affecting gay and bisexual men. That spike was driven by a new subtype, dubbed Clade II, which took over from Clade I. Around 140 people died out of about 90,000 cases across 111 countries.

The outbreak is “still raging”, Lewis said, including in South Africa, which has seen 24 cases, three of which were fatal, but she added it was “controlled” and spreading less.

Mpox remains a global health threat, WHO chief Tedros Adhanom Ghebreyesus warned in early July.

Countries are now able to detect cases, Lewis said, pointing to a system of surveillance, laboratories and communication with affected areas. It is hard to know if there has been “a substantial rise” in cases, or whether “it’s just a matter of increased awareness”, said Maria Van Kerkhove, the WHO’s epidemic and pandemic preparedness and prevention director, who confirmed concern over the Clade Ib strain.

“There are some vaccines that are licensed that can be used for mpox,” she said.

Negotiations between the WHO and affected countries are under way to authorise the use of one, Lewis said.



Source link

]]>
The ‘genomic accordion’ mpox viruses use to evolve, infect humans https://artifex.news/article68090535-ece/ Mon, 22 Apr 2024 00:00:00 +0000 https://artifex.news/article68090535-ece/ Read More “The ‘genomic accordion’ mpox viruses use to evolve, infect humans” »

]]>

Poxviruses have long been a cause of fear as well as curiosity for humankind. One particularly infamous poxvirus, smallpox, alone may have killed more than 500 million people in the last century.

Smallpox didn’t discriminate between rich, poor, young, old, and killed a third of the individuals whom it infected. The turning point came with evidence of the efficacy of the smallpox vaccine. Thus followed a concerted effort worldwide to administer the vaccine and eventually eradicate the dread disease. This feat has stood as a testament to the power of sustained global public health initiatives.

Mpox’s 15 minutes

Another poxvirus, mpox, was recently in the headlines after a rapidly expanding global outbreak in 2022-2023. The virus was previously called ‘monkeypox’ after a spillover event in a research facility involving monkeys in 1958; the name is considered both wrong and inappropriate today: since then, researchers have identified mpox in many sporadic outbreaks among humans. They have also found multiple mpox lineages have been circulating in humans, adapting by accumulating mutations modulated largely by the APOBEC proteins.

But it wasn’t until 2022 that the disease became widely known, thanks to outbreaks in more than 118 countries and the World Health Organisation (WHO) quickly declaring it a public health emergency. To date, this outbreak has infected almost 100,000 people. Based on WHO data, infections have a mortality rate of 1-10%.

The outbreak was due to one clade (strains of the virus descended from a common ancestor) — called IIb — having developed very high human-to-human transmission through close contact and spread through the sexual route. While the rate of new infections has been dropping, mpox continues to circulate among unvaccinated individuals worldwide. This increases the chance that a more virulent and transmissible strain might emerge and become endemic somewhere.

Expanding, contracting as required

Mpox, like all poxviruses, are DNA viruses. The mpox genome has about 197 kilobases (kb). The core genes are those closely conserved (i.e. preserved during evolution) by various poxviruses plus two sections about 6.4 kb long, one at each end of the genome. Researchers don’t yet know what function these sections serve but suspect they influence how well the poxviruses can infect different hosts.

The mpox genome also has a sequence of bases repeating in a pattern, which researchers believe play a role in the virus’s evolution.

The mpox family of viruses is also known to be able to evade selective evolutionary pressures. It does this by duplicating genes and/or accumulating mutations and expanding its genome significantly — or contracting its genome by deleting gene stretches or inactivating them. Such rhythmic expansions and contractions are called genomic accordions.

Find the accordion

In a study published on April 18 by Nature Communications, researchers at the Icahn School of Medicine in New York and multiple institutions in Spain extensively sequenced the genome of the mpox virus implicated in the 2022 outbreak. They used advanced genome sequencing technologies to piece together a comprehensive genome of the mpox virus from scratch.

They found that the 6.4-kb-long sections of the virus strongly influenced the virus’s human-to-human transmissibility. They also reported that variations in three genes in particular could affect the virus’s evolution. Importantly, 6.4-kb-long sections, which scientists had previously considered to be not so informative, were actually found to be the virus’s genomic accordions.

All mpox genomes can be divided into two distinct yet broad clades: I and II. Clade I is thought to have a higher mortality. Each clade has sub-clades, or lineages, defined by specific evolutionary processes. Researchers have also found evidence of significantly different mpox virulence in animal models. The new study, like others like it, further the idea that the 2022 outbreak largely involved a new lineage of the virus, clade IIb, that was even better adapted to human-to-human transmission than clades I or IIa.

The outbreak in the DRC

Between September 2023 and February 2024, health workers detected a large mpox outbreak detected in the Democratic Republic of the Congo (DRC), centred on a mining village and quickly spreading to a number of regions within the country. This outbreak was associated with a significantly larger spread as well as mortality. Researchers soon confirmed mpox clade I was responsible.

This outbreak differed from earlier ones, which were sporadic and self-contained spillover events, by spreading through human-to-human contact and affecting young adults rather than children. A preprint paper, uploaded by researchers from Belgium, Canada, the DRC, France, Ghana, Nigeria, South Africa, and the U.S., on April 14 describes the genomes of virus samples obtained from 241 individuals suspected to have been infected during the outbreak.

The genomic data suggests a distinct lineage of clade I being associated with human-to-human transmission. The researchers also found evidence — in fragments of the genome that closely resembled viruses isolated and sequenced in recent years — of the hypothesis that this lineage emerged from a very recent zoonotic spillover.

One eye on the genome

As with any viral infection, without urgent intervention, the outbreak has the potential to spread rapidly across national, and even continental, boundaries and emerge as another global outbreak.

To prevent such an outcome, genome sequences from before and during mpox outbreaks have provided well-lit glimpses of the evolutionary dynamics the virus uses to invent new ways to move between and survive in different populations of animals and people.

Thus, through rigorous genomic investigations and coordinated public health efforts, we can mitigate the threat of emerging pathogens and the world’s health security.

The authors are senior consultants at the Vishwanath Cancer Care Foundation and Adjunct Professors at Indian Institute of Technology Kanpur. All opinions expressed are personal.



Source link

]]>